Non-invasive skin cholesterol testing: a potential proxy for LDL-C and apoB serum measurements.
Non-invasive skin cholesterol testing: a potential proxy for LDL-C and apoB serum measurements.
复制标题
DOI：
10.1186/s12944-021-01571-0
复制
发表时间：
2021-10-17
影响因子：
4.5
通讯作者：
Wang Q
中科院分区：
文献类型：
--
作者：
Lai J;Han Y;Huang C;Li B;Ni J;Dong M;Wang Y;Wang Q
脂质管理是降低冠心病（冠心病）患者心血管事件发生率的第一线治疗，多种指标用于评价脂质管理。这项工作分析了LDL-C和载脂蛋白ob在脂质管理评估中的差异，并探讨了皮肤胆固醇作为一种可以无创测量的脂质管理标志物的可行性。前瞻性研究纳入2020年5月至2021年1月在中国科学技术大学第一附属医院急诊科诊断为急性冠脉综合征（ACS）的患者121例，根据患者是否合并高脂血症和/或糖尿病分为I组（n=53）和II组（n=68）。所有患者均给予瑞舒伐他汀10 mg/天，观察12周。脂质管理在LDL-C和载脂蛋白ob的基础上进行评估，并采用线性相关模型来评估这些广为接受的标记物的变化与皮肤胆固醇变化之间的关系。121例ACS患者中，53例（43.80%）合并高脂血症和/或糖尿病（I组），68例（56.20%）未合并高脂血症和/或糖尿病（II组）。合并高脂血症和/或糖尿病的冠心病患者发生心血管事件的年龄更早（P<0.05）。瑞舒伐他汀组LDL-C完成率低于apoB完成率（P<0.05），这主要是由于患者初始LDL-C较低所致。皮肤胆固醇降低与LDL-C降低相关。（r=0.501， P<0.001）和apoB降低（r=0.538， P<0.001）。在所有测量的时间点上，皮肤胆固醇持续下降。与LDL-C读数相比，检查载脂蛋白ob水平的变化可以为低初始LDL-C患者提供更多关于脂质管理的信息。此外，非侵入性皮肤胆固醇测量可能有潜力独立用于脂质管理评估。
Lipid management is the first line of treatment for decreasing the incidence of cardiovascular events in patients with coronary heart disease (CHD), and a variety of indicators are used to evaluate lipid management. This work analyses the differences in LDL-C and apoB for lipid management evaluation, as well as explores the feasibility of skin cholesterol as a marker that can be measured non-invasively for lipid management. The prospective study enrolled 121 patients who had been diagnosed with acute coronary syndrome (ACS) at the department of emergency medicine of the First Affiliated Hospital of the USTC from May 2020 to January 2021, and the patients were grouped into Group I (n=53) and Group II (n=68) according to whether they had comorbid hyperlipidemia and/or diabetes mellitus. All patients were administered 10 mg/day of rosuvastatin and observed for 12 weeks. Lipid management was assessed on the basis of LDL-C and apoB, and linear correlation models were employed to assess the relationship between changes in these well accepted markers to that of changes in skin cholesterol. Out of 121 patients with ACS, 53 patients (43.80 %) had combined hyperlipidemia and/or diabetes mellitus (Group I), while 68 patients (56.20 %) did not (Group II). Cardiovascular events occur at earlier ages in patients with CHD who are comorbid for hyperlipidemia and/or diabetes (P<0.05). LDL-C attainment rate is lower than apoB attainment rate with rosuvastatin therapy (P<0.05), which is mainly attributable to patients with low initial LDL-C. Skin cholesterol reduction correlated with LDL-C reduction. (r=0.501, P<0.001) and apoB reduction (r=0.538, P<0.001). Skin cholesterol reduction continued over all time points measured. Examination of changes in apoB levels give patients with low initial LDL-C more informative data on lipid management than LDL-C readings. In addition, non-invasive skin cholesterol measurements may have the potential to be used independently for lipid management evaluation.
登录
查看更多内容
DOI：
10.1016/j.bbalip.2019.158592
发表时间：
2020-03-01
影响因子：
4.8
作者：
Cardoso, Renata Martins;Creemers, Eline;Van Eck, Miranda
通讯作者：
Van Eck, Miranda
影响因子：
2.8
作者：
Stein, James H.;Tzou, Wendy S.;Davidson, Michael H.
通讯作者：
Davidson, Michael H.
影响因子：
3.9
作者：
Ni J;Hong H;Zhang Y;Tang S;Han Y;Fang Z;Zhang Y;Zhou N;Wang Q;Liu Y;Li Z;Wang Y;Dong M
通讯作者：
Dong M
影响因子：
--
作者：
Gaspar, I. M.;Gaspar, A.
通讯作者：
Gaspar, A.
影响因子：
2.3
作者：
Hu, Hao;Gao, Yak;Jiang, Hua
通讯作者：
Jiang, Hua